Latest Breaking News On - Lungen clinic - Page 1 : vimarsana.com

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSchleswig holsteinHenrik watzDennis riedlDave singhMaria bechGinny norrisPulmonary research instituteEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumEndo pharmaceuticalsChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacology

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

United kingdomSchleswig holsteinGinny norrisMaria bechDave singhHenrik watzEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumPulmonary research instituteChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacologyMedical directorMedicines evaluation unit

Researchers find dupilumab reduces disease in COPD patients with type 2 inflammation

Researchers find dupilumab reduces disease in COPD patients with type 2 inflammation
newkerala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newkerala.com Daily Mail and Mail on Sunday newspapers.

Himachal pradeshUnited statesSurya bhattKlaus rabeDevinder sandhuUniversity of kielWorld health organizationNew england journalBirmingham departmentMedicine divisionCritical care medicineLungen clinic

Treatment with dupilumab leads to sustained improvements in COPD patients with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.

United statesLily ramseySurya bhattKlaus rabeUniversity of kielAmerican thoracic societyMarnixe heersink school of medicineInternational conferenceWorld health organizationNew england journalBirmingham departmentMedicine divisionCritical care medicineLungen clinic

Researchers find dupilumab reduces disease in COPD patients with type 2 inflammation

Researchers find dupilumab reduces disease in COPD patients with type 2 inflammation
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United statesSurya bhattKlaus rabeUniversity of kielWorld health organizationNew england journalBirmingham departmentMedicine divisionCritical care medicineLungen clinic